Tristel is a manufacturer of infection control, contamination control and hygiene products. It has three principal activities:
– Hospital infection prevention and control under the Tristel brand
– Contamination control in the pharmaceutical and personal care industry under the Crystel brand
– Animal health infection prevention and control under the Anistel brand
The Tristel story began in 1993 when the founding shareholders developed a proprietary chlorine dioxide formulation to be used for the disinfection of flexible endoscopes to replace glutaraldehyde. Glutaraldehyde was at the time used universally throughout all hospitals in the United Kingdom, and indeed worldwide, for the disinfection of heat-sensitive medical instruments. However, it was known to be toxic.
During the course of the following decade Tristel gradually captured significant market share in the United Kingdom hospital market. In June 2005 Tristel plc was listed on the London Stock Exchange AIM market.
By this time the Company had developed a broader vision for the use of its chlorine dioxide chemistry and had set in train its strategy to apply the chemistry to the four vectors of transmission of infection in a hospital: instruments, surfaces, water and skin.
A key milestone in the development of the Tristel group was the establishment of its manufacturing plant in Cambridgeshire in 2007.
Having established its capability as an ISO 9001:2008 and BS EN 13485:2003 manufacturer of high-level disinfectants, in 2009 Tristel acquired the intellectual property and manufacturing rights for a portfolio of disinfectants used in animal healthcare facilities worldwide. Tristel manufactured these products until March 2012 when it created its Anistel brand and has since served the animal healthcare market directly.
Tristel now has established subsidiaries and associated companies in New Zealand, Hong Kong, China, Italy and branch operations in Germany and Russia.